Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for Israeli Healthcare Professionals only.

      Main Banner Ozurdex 1900X400px

      OZURDEX® Indications and Coverage

      BRVO- branch retinal vein occlusion ; CRVO- central retinal vein occlusion ; TIA- transient ischemic attack

      Ozurdex indications and coverage Table_v2

      *Bevacizumab is not licensed for ophthalmic use.  Abbvie does not endorse unlicensed use of any product.

      ^For full information please refer to the ministry of health (MOH) circular for the national health basket expansion 2025.

      Refrences:

      1. OZURDEX® Prescribing Information.
      2. Garcia-Layana A et al. Ophthalmologica 2018; doi: 10.1159/000486800 (accessed September 2023).
      3. Wang K et al. Biol Pharm Bull 2008; 31(8): 1541-6.
      4. Rezar-Dreindl S et al. Acta Ophthalmol 2017; 95(2): e119-27. http://dx.doi.org/10.1155/2013/438412 (accessed September 2023).
      5. 5. Edelman JL et al. Exp Eye Res 2005; 80: 249-58
      6. Tamura H et al. Invest Ophthalmol Vis Sci 2005; 46(4): 1440-4.
      7. Nehme A and Edelman J. Invest Ophthalmol Vis Sci 2008; 49(5): 2030-8.

      Full Prescribing Information >>

      IL-OZU-250013 MAY2025